Cargando…

Efficacy and safety of a 3-month loteprednol etabonate 0.5% gel taper for routine prophylaxis after photorefractive keratectomy compared to a 3-month prednisolone acetate 1% and fluorometholone 0.1% taper

PURPOSE: To compare the outcome of photorefractive keratectomy (PRK) and complications in patients treated with either loteprednol etabonate 0.5% gel or prednisolone acetate 1% suspension and fluorometholone (fml) 0.1% suspension. SETTING: John A Moran Eye Center, University of Utah, Salt Lake City,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mifflin, Mark D, Betts, Brent S, Frederick, P Adam, Feuerman, Jason M, Fenzl, Carlton R, Moshirfar, Majid, Zaugg, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476723/ https://www.ncbi.nlm.nih.gov/pubmed/28652697 http://dx.doi.org/10.2147/OPTH.S138272

Ejemplares similares

Comparison of Loteprednol with Fluorometholone after Myopic Photorefractive Keratectomy
por: Karimian, Farid, et al.
Publicado: (2017)

Use of loteprednol for routine prophylaxis after photorefractive keratectomy
por: Mifflin, Mark D, et al.
Publicado: (2012)

A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery
por: Salinger, Clifford L, et al.
Publicado: (2015)

Comparison between Betamethasone, Fluorometholone and Loteprednol Etabonate on intraocular pressure in patients after keratorefractive surgery
por: Shokoohi-Rad, Saeed, et al.
Publicado: (2017)

Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis
por: Mah, Francis S., et al.
Publicado: (2021)

Dose Uniformity of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38% Compared with Prednisolone Acetate Ophthalmic Suspension 1%
por: Marlowe, Zora T., et al.
Publicado: (2021)

Corneal biomechanical properties after laser-assisted in situ keratomileusis and photorefractive keratectomy
por: Hwang, Eileen S, et al.
Publicado: (2017)

Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
por: Marlowe, Zora T, et al.
Publicado: (2014)

Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation
por: Schopf, Lisa, et al.
Publicado: (2014)

Loteprednol Etabonate for the Treatment of Dry Eye Disease
por: Beckman, Kenneth, et al.
Publicado: (2020)

Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use
por: Amon, Michael, et al.
Publicado: (2012)

A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
por: Khaimi, Mahmoud A
Publicado: (2018)

Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate
por: Comstock, Timothy L., et al.
Publicado: (2012)

Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%
por: Cavet, Megan E., et al.
Publicado: (2019)

Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease
por: Venkateswaran, Nandini, et al.
Publicado: (2022)

Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
por: Comstock, Timothy L, et al.
Publicado: (2011)

Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients
por: Özcan, Gökçen, et al.
Publicado: (2021)

An update on the surgical management of pterygium and the role of loteprednol etabonate ointment
por: Sheppard, John D, et al.
Publicado: (2014)

Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure
por: Sheppard, John D., et al.
Publicado: (2016)

Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
por: Deom, James E, et al.
Publicado: (2022)

Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial
por: Fong, Raymond, et al.
Publicado: (2012)

Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
por: Coffey, Martin J, et al.
Publicado: (2013)

High myopic photorefractive keratectomy outcomes with the Alcon Wavelight(®) EX500 excimer laser
por: Mifflin, Mark D, et al.
Publicado: (2018)

Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery
por: Kang, Connie, et al.
Publicado: (2020)

Prospective, randomized, contralateral eye comparison of tetracaine and proparacaine for pain control in laser in situ keratomileusis and photorefractive keratectomy
por: Moshirfar, Majid, et al.
Publicado: (2014)

Comparing the Rate of Regression after Conductive Keratoplasty with or without Prior Laser-Assisted in situ Keratomileusis or Photorefractive Keratectomy
por: Moshirfar, Majid, et al.
Publicado: (2012)

A prospective, contralateral comparison of photorefractive keratectomy (PRK) versus thin-flap LASIK: assessment of visual function
por: Hatch, Bryndon B, et al.
Publicado: (2011)

Binary Polymeric Surfactant Mixtures for the Development of Novel Loteprednol Etabonate Nanomicellar Eyedrops
por: Tampucci, Silvia, et al.
Publicado: (2023)

Use of angle kappa in myopic photorefractive keratectomy
por: Khakshoor, Hamid, et al.
Publicado: (2015)

Correction to: Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Infammation and Pain Following Ocular Surgery
por: Kang, Connie, et al.
Publicado: (2020)

Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle‐controlled study
por: Liu, Rui‐fen, et al.
Publicado: (2016)

Management of Corneal Haze After Photorefractive Keratectomy
por: Moshirfar, Majid, et al.
Publicado: (2023)

Loteprednol etabonate: Dematiaceous fungal colonisation by Bipolaris species in the left eye: case report
Publicado: (2020)

Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
por: Sheppard, JD, et al.
Publicado: (2019)

Survey of Postoperative Pain in Photorefractive Keratectomy Using Topical versus Oral Nonsteroidal Anti-Inflammatory Drugs
por: Ripa, Madeline, et al.
Publicado: (2020)

Photorefractive Keratectomy in Keratoconus
por: Tambe, Deepali Sandeep, et al.
Publicado: (2015)

Transepithelial Photorefractive Keratectomy for Low to Moderate Myopia in Comparison with Conventional Photorefractive Keratectomy
por: Naderi, Mostafa, et al.
Publicado: (2016)

Transepithelial Photorefractive Keratectomy Compared to Conventional Photorefractive Keratectomy: A Meta-Analysis
por: Alasbali, Tariq
Publicado: (2022)

Comparative analysis of safety and efficacy of photorefractive keratectomy versus photorefractive keratectomy combined with crosslinking
por: Sachdev, Gitansha Shreyas, et al.
Publicado: (2018)

Herpes endotheliitis following laser-assisted in situ keratomileusis and photorefractive keratectomy
por: Moshirfar, Majid, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_49i2026ce0blv4ear6acgjtqgn